Oramed Pharmaceuticals Stock EBITDA
| ORMP Stock | USD 2.33 0.07 2.92% |
Oramed Pharmaceuticals fundamentals help investors to digest information that contributes to Oramed Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Oramed Stock. The fundamental analysis module provides a way to measure Oramed Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Oramed Pharmaceuticals stock.
| Last Reported | Projected for Next Year | ||
| EBITDA | -33.3 M | -31.6 M |
Oramed | EBITDA |
Oramed Pharmaceuticals Company EBITDA Analysis
Oramed Pharmaceuticals' EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Current Oramed Pharmaceuticals EBITDA | (36.98 M) |
Most of Oramed Pharmaceuticals' fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Oramed Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Oramed EBITDA Driver Correlations
Understanding the fundamental principles of building solid financial models for Oramed Pharmaceuticals is extremely important. It helps to project a fair market value of Oramed Stock properly, considering its historical fundamentals such as EBITDA. Since Oramed Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Oramed Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Oramed Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
| Competition |
Oramed Ebitda
According to the company disclosure, Oramed Pharmaceuticals reported earnings before interest,tax, depreciation and amortization of (36.98 Million). This is 104.21% lower than that of the Pharmaceuticals sector and 136.92% lower than that of the Health Care industry. The ebitda for all United States stocks is 100.95% higher than that of the company.
Oramed EBITDA Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Oramed Pharmaceuticals' direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Oramed Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Oramed Pharmaceuticals by comparing valuation metrics of similar companies.Oramed Pharmaceuticals is currently under evaluation in ebitda category among related companies.
Oramed Pharmaceuticals Current Valuation Drivers
We derive many important indicators used in calculating different scores of Oramed Pharmaceuticals from analyzing Oramed Pharmaceuticals' financial statements. These drivers represent accounts that assess Oramed Pharmaceuticals' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Oramed Pharmaceuticals' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 57.9M | 71.7M | 560.3M | 469.1M | 422.2M | 443.3M | |
| Enterprise Value | 54.6M | 52.4M | 483.6M | 429.6M | 386.6M | 405.9M |
Oramed Pharmaceuticals Institutional Holders
Institutional Holdings refers to the ownership stake in Oramed Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Oramed Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Oramed Pharmaceuticals' value.| Shares | Qube Research & Technologies | 2023-12-31 | 86.5 K | Morgan Stanley - Brokerage Accounts | 2023-12-31 | 64.2 K | State Street Corporation | 2023-12-31 | 58 K | Susquehanna International Group, Llp | 2023-12-31 | 45.9 K | Lpl Financial Corp | 2023-12-31 | 43.2 K | Jpmorgan Chase & Co | 2023-12-31 | 28.8 K | Pnc Financial Services Group Inc | 2023-12-31 | 26.2 K | Geode Capital Management, Llc | 2023-12-31 | 25.5 K | American Century Companies Inc | 2023-12-31 | 19.3 K | Bml Capital Management Llc | 2023-12-31 | 1.3 M | Murchinson Ltd. | 2023-12-31 | 1.1 M |
Oramed Fundamentals
| Return On Equity | 0.0324 | ||||
| Return On Asset | -0.0516 | ||||
| Profit Margin | 4.12 % | ||||
| Operating Margin | (11.77) % | ||||
| Current Valuation | (22.21 M) | ||||
| Shares Outstanding | 40.52 M | ||||
| Shares Owned By Insiders | 11.20 % | ||||
| Shares Owned By Institutions | 13.88 % | ||||
| Number Of Shares Shorted | 583.94 K | ||||
| Price To Earning | (11.22) X | ||||
| Price To Book | 0.62 X | ||||
| Price To Sales | 76.20 X | ||||
| Revenue | 2.7 M | ||||
| Gross Profit | 2.7 M | ||||
| EBITDA | (36.98 M) | ||||
| Net Income | (37.76 M) | ||||
| Cash And Equivalents | 133.91 M | ||||
| Cash Per Share | 3.45 X | ||||
| Total Debt | 894 K | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 21.01 X | ||||
| Book Value Per Share | 4.06 X | ||||
| Cash Flow From Operations | (27.92 M) | ||||
| Short Ratio | 3.95 X | ||||
| Earnings Per Share | 0.14 X | ||||
| Target Price | 4.25 | ||||
| Beta | 1.82 | ||||
| Market Capitalization | 89.14 M | ||||
| Total Asset | 161.64 M | ||||
| Retained Earnings | (163.08 M) | ||||
| Working Capital | 109.37 M | ||||
| Current Asset | 31 M | ||||
| Current Liabilities | 4 M | ||||
| Net Asset | 161.64 M |
About Oramed Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Oramed Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Oramed Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Oramed Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Oramed Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Oramed Pharmaceuticals' short interest history, or implied volatility extrapolated from Oramed Pharmaceuticals options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Oramed Pharmaceuticals Piotroski F Score and Oramed Pharmaceuticals Altman Z Score analysis. To learn how to invest in Oramed Stock, please use our How to Invest in Oramed Pharmaceuticals guide.You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.
Complementary Tools for Oramed Stock analysis
When running Oramed Pharmaceuticals' price analysis, check to measure Oramed Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Oramed Pharmaceuticals is operating at the current time. Most of Oramed Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Oramed Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Oramed Pharmaceuticals' price. Additionally, you may evaluate how the addition of Oramed Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency |
Is Oramed Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Oramed Pharmaceuticals. If investors know Oramed will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Oramed Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 0.14 | Revenue Per Share 0.033 | Quarterly Revenue Growth (1.00) | Return On Assets (0.05) | Return On Equity 0.0324 |
The market value of Oramed Pharmaceuticals is measured differently than its book value, which is the value of Oramed that is recorded on the company's balance sheet. Investors also form their own opinion of Oramed Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Oramed Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Oramed Pharmaceuticals' market value can be influenced by many factors that don't directly affect Oramed Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Oramed Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Oramed Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Oramed Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.